Mechanistic links between COPD and lung cancer

Nature Reviews Cancer

Volumn 13, Issue 4, 2013, Pages 233-245

  Houghton, A McGarry ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CORTICOSTEROID; ILOPROST; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

AIRWAY OBSTRUCTION; ANTIPROLIFERATIVE ACTIVITY; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG MECHANISM; EMPHYSEMA; EXTRACELLULAR MATRIX; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATION; LUNG CANCER; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SMALL CELL LUNG CARCINOMA;

EID: 84875466646     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3477     Document Type: Review

References (169)

1. Peto, R., Chen, Z. M. & Boreham, J. Tobacco-the growing epidemic. Nature Med. 5, 15-17 (1999).
2. Youlden, D. R., Cramb, S. M. & Baade, P. D. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J. Thorac. Oncol. 3, 819-831 (2008).
3. Wasswa-Kintu, S., Gan, W. Q., Man, S. F., Pare, P. D. & Sin, D. D. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax 60, 570-575 (2005).
4. Skillrud, D. M., Offord, K. P. & Miller, R. D. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann. Intern. Med. 105, 503-507 (1986).
5. Tockman, M. S., Anthonisen, N. R., Wright, E. C. & Donithan, M. G. Airways obstruction and the risk for lung cancer. Ann. Intern. Med. 106, 512-518 (1987).
6. Lange, P., Nyboe, J., Appleyard, M., Jensen, G. & Schnohr, P. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. Am. Rev. Respir. Dis. 141, 613-617 (1990).
7. Speizer, F. E., Fay, M. E., Dockery, D. W. & Ferris, B. G. Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am. Rev. Respir. Dis. 140, S49-S55 (1989).
8. Sin, D. D., Anthonisen, N. R., Soriano, J. B. & Agusti, A. G. Mortality in COPD: role of comorbidities. Eur. Respir. J. 28, 1245-1257 (2006).
9. Young, R. P. et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir. J. 34, 380-386 (2009).
10. Pauwels, R. A., Buist, A. S., Calverley, P. M., Jenkins, C. R. & Hurd, S. S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 163, 1256-1276 (2001).
11. Shapiro, S. D. & Ingenito, E. P. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am. J. Respir. Cell. Mol. Biol. 32, 367-372 (2005).
12. Mannino, D. M. Epidemiology and global impact of chronic obstructive pulmonary disease. Semin. Respir. Crit. Care Med. 26, 204-210 (2005).
13. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
14. Travis, W. D. et al. International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc. Am. Thorac. Soc. 8, 381-385 (2011).
15. Sun, S., Schiller, J. H. & Gazdar, A. F. Lung cancer in never smokers-a different disease. Nature Rev. Cancer 7, 778-790 (2007).
16. Punturieri, A., Szabo, E., Croxton, T. L., Shapiro, S. D. & Dubinett, S. M. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. J. Natl Cancer Inst. 101, 554-559 (2009).
17. Wilson, D. O. et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am. J. Respir. Crit. Care Med. 178, 738-744 (2008).
18. Ueda, K. et al. Computed tomography-diagnosed emphysema, not airway obstruction, is associated with the prognostic outcome of early-stage lung cancer. Clin. Cancer Res. 12, 6730-6736 (2006).
19. de Torres, J. P. et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 132, 1932-1938 (2007).
20. Li, Y. et al. Effect of emphysema on lung cancer risk in smokers: a computed tomography-based assessment. Cancer Prev. Res. 4, 43-50 (2011).
21. Zulueta, J. J. et al. Emphysema scores predict death from COPD and lung cancer. Chest 141, 1216-1223 (2012).
22. Wilson, D. O. et al. Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the pittsburgh lung screening study. J. Thorac. Oncol. 6, 1200-1205 (2011).
23. Maldonado, F. et al. Are airflow obstruction and radiographic evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema analysis. Chest 138, 1295-1302 (2010).
24. Taraseviciene-Stewart, L. & Voelkel, N. F. Molecular pathogenesis of emphysema. J. Clin. Invest. 118, 394-402 (2008).
25. Barnes, P. J. Chronic obstructive pulmonary disease. N. Engl. J. Med. 343, 269-280 (2000).
26. Berk, D. R., Bentley, D. D., Bayliss, S. J., Lind, A. & Urban, Z. Cutis laxa: a review. J. Am. Acad. Dermatol. 66, 842.e1-842.e17 (2012).
27. Brantly, M., Nukiwa, T. & Crystal, R. G. Molecular basis of α-1-antitrypsin deficiency. Am. J. Med. 84, 13-31 (1988).
28. Shapiro, S. D., Endicott, S. K., Province, M. A., Pierce, J. A. & Campbell, E. J. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weapons-related radiocarbon. J. Clin. Invest. 87, 1828-1834 (1991).
29. Heidelberger, K. P. α-1-antitrypsin deficiency: a review; 1963-1975. Ann. Clin. Lab Sci. 6, 110-117 (1976).
30. Shapiro, S. D. The pathogenesis of emphysema: the elastase:antielastase hypothesis 30 years later. Proc. Assoc. Am. Physicians 107, 346-352 (1995).
31. Gross, P., Pfitzer, E. A., Tolker, E., Babyak, M. A. & Kaschak, M. Experimental emphysema: its production with papain in normal and silicotic rats. Arch. Environ. Health 11, 50-58 (1965).
32. Larsson, C. Natural history and life expectancy in severe α1-antitrypsin deficiency, Pi Z. Acta Med. Scand. 204, 345-351 (1978).
33. Yang, P. et al. α1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch. Intern. Med. 168, 1097-1103 (2008).
34. Yang, P. et al. α1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest 128, 445-452 (2005).
35. Petrache, I. et al. A novel antiapoptotic role for α1-antitrypsin in the prevention of pulmonary emphysema. Am. J. Respir. Crit. Care Med. 173, 1222-1228 (2006).
36. Demeo, D. L. et al. The SERPINE2 gene is associated with chronic obstructive pulmonary disease. Am. J. Hum. Genet. 78, 253-264 (2006).
37. Cho, M. H. et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nature Genet. 42, 200-202 (2010).
38. Pillai, S. G. et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 182, 1498-1505 (2010).
39. Thorgeirsson, T. E. et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638-642 (2008).
40. Hung, R. J. et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633-637 (2008).
41. Amos, C. I. et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nature Genet. 40, 616-622 (2008).
42. Belinsky, S. A. et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 62, 2370-2377 (2002).
43. Belinsky, S. A. Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26, 1481-1487 (2005).
44. Zhang, H. T. et al. Defective expression of transforming growth factor β receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin. Cancer Res. 10, 2359-2367 (2004).
45. Zochbauer-Muller, S. et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 61, 249-255 (2001).
46. Ohtani-Fujita, N. et al. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8, 1063-1067 (1993).
47. Dammann, R., Takahashi, T. & Pfeifer, G. P. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 20, 3563-3567 (2001).
48. Belinsky, S. A. et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891-11896 (1998).
49. Qiu, W. et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am. J. Respir. Crit. Care Med. 185, 373-381 (2012).
50. Kasahara, Y. et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Invest. 106, 1311-1319 (2000).
51. Aoshiba, K., Yokohori, N. & Nagai, A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am. J. Respir. Cell. Mol. Biol. 28, 555-562 (2003).
52. Shapiro, S. D. Vascular atrophy and VEGFR-2 signaling: old theories of pulmonary emphysema meet new data. J. Clin. Invest. 106, 1309-1310 (2000).
53. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
54. Steiling, K., Ryan, J., Brody, J. S. & Spira, A. The field of tissue injury in the lung and airway. Cancer Prev. Res. 1, 396-403 (2008).
55. Slaughter, D. P., Southwick, H. W. & Smejkal, W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963-968 (1953).
56. Franklin, W. A. et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J. Clin. Invest. 100, 2133-2137 (1997).
57. Chang, Y. L. et al. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin. Cancer Res. 13, 52-58 (2007).
58. Wistuba, I. I. et al. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl Cancer Inst. 89, 1366-1373 (1997).
59. Tang, X. et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 65, 7568-7572 (2005).
60. Ji, H. et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25, 2105-2112 (2006).
61. Sparmann, A. & Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6, 447-458 (2004).
62. Spira, A. et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nature Med. 13, 361-366 (2007).
63. Gustafson, A. M. et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2, 26ra25 (2010).
64. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
65. Kim, C. F. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835 (2005).
66. Yatabe, Y., Borczuk, A. C. & Powell, C. A. Do all lung adenocarcinomas follow a stepwise progression? Lung Cancer 74, 7-11 (2011).
67. Karimi, R., Tornling, G., Grunewald, J., Eklund, A. & Skold, C. M. Cell recovery in bronchoalveolar lavage fluid in smokers is dependent on cumulative smoking history. PLoS ONE 7, e34232 (2012).
68. Merchant, R. K., Schwartz, D. A., Helmers, R. A., Dayton, C. S. & Hunninghake, G. W. Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am. Rev. Respir. Dis. 146, 448-453 (1992).
69. Hogg, J. C. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350, 2645-2653 (2004).
70. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
71. Grumelli, S. et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med. 1, e8 (2004).
72. Shaykhiev, R. et al. Smoking-dependent reprogramming of alveolar macrophage polarization: implication for pathogenesis of chronic obstructive pulmonary disease. J. Immunol. 183, 2867-2883 (2009).
73. Kunz, L. I. et al. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir. Res. 12, 34 (2011).
74. Maeno, T. et al. CD8+ T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J. Immunol. 178, 8090-8096 (2007).
75. Mio, T. et al. Cigarette smoke induces interleukin-8 release from human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 155, 1770-1776 (1997).
76. Shan, M. et al. Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema. Sci. Transl. Med. 1, 4ra10 (2009).
77. Chen, K. et al. IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS ONE 6, e20333 (2011).
78. de Visser, K. E., Eichten, A. & Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nature Rev. Cancer 6, 24-37 (2006).
79. Mantovani, A., Sozzani, S., Locati, M., Allavena, P. & Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23, 549-555 (2002).
80. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
81. Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 16, 183-194 (2009).
82. Moghaddam, S. J. et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am. J. Respir. Cell. Mol. Biol. 40, 443-453 (2009).
83. Gallina, G. et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116, 2777-2790 (2006).
84. Chen, M. L. et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl Acad. Sci. USA 102, 419-424 (2005).
85. Whiteside, T. L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16, 3-15 (2006).
86. Wang, L. et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206, 1457-1464 (2009).
87. Martin-Orozco, N. et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31, 787-798 (2009).
88. Haqqani, A. S., Sandhu, J. K. & Birnboim, H. C. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia 2, 561-568 (2000).
89. Dinarello, C. A. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 25, 307-313 (2006).
90. Takahashi, H., Ogata, H., Nishigaki, R., Broide, D. H. & Karin, M. Tobacco smoke promotes lung tumorigenesis by triggering IKKβ- and JNK1-dependent inflammation. Cancer Cell 17, 89-97 (2010).
91. Zhang, J. Y., Wang, Y. & Prakash, C. Xenobiotic-metabolizing enzymes in human lung. Curr. Drug Metab. 7, 939-948 (2006).
92. Dix, T. A. & Marnett, L. J. Metabolism of polycyclic aromatic hydrocarbon derivatives to ultimate carcinogens during lipid peroxidation. Science 221, 77-79 (1983).
93. Feyler, A. et al. Point: myeloperoxidase -463G - a polymorphism and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 1550-1554 (2002).
94. Nguyen, T., Nioi, P. & Pickett, C. B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 284, 13291-13295 (2009).
95. Rangasamy, T. et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 114, 1248-1259 (2004).
96. Satoh, H. et al. Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis 31, 1833-1843 (2010).
97. Kensler, T. W. et al. Modulation of the metabolism of airborne pollutants by glucoraphanin-rich and sulforaphane-rich broccoli sprout beverages in Qidong, China. Carcinogenesis 33, 101-107 (2012).
98. Shureiqi, I. & Baron, J. A. Curcumin chemoprevention: the long road to clinical translation. Cancer Prev. Res. 4, 296-298 (2011).
99. DeNicola, G. M. et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106-109 (2011).
100. Sporn, M. B. & Liby, K. T. NRF2 and cancer: the good, the bad and the importance of context. Nature Rev. Cancer 12, 564-571 (2012).
101. Solis, L. M. et al. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin. Cancer Res. 16, 3743-3753 (2010).
102. Liu, Z. et al. The serpin α1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102, 647-655 (2000).
103. Atkinson, J. J. et al. The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am. J. Respir. Crit. Care Med. 183, 876-884 (2011).
104. Russell, R. E. et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol. 26, 602-609 (2002).
105. Russell, R. E. et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am. J. Physiol. Lung Cell. Mol. Physiol. 283, L867-L873 (2002).
106. Vignola, A. M. et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am. J. Respir. Crit. Care Med. 158, 1945-1950 (1998).
107. Nozawa, H., Chiu, C. & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493-12498 (2006).
108. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737-744 (2000).
109. Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481-490 (2000).
110. Itoh, T. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58, 1048-1051 (1998).
111. Gupta, G. P. et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765-770 (2007).
112. Lu, X. et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 23, 1882-1894 (2009).
113. Minn, A. J. et al. Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
114. D'Armiento, J., Dalal, S. S., Okada, Y., Berg, R. A. & Chada, K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 71, 955-961 (1992).
115. Joos, L. et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum. Mol. Genet. 11, 569-576 (2002).
116. Hautamaki, R. D., Kobayashi, D. K., Senior, R. M. & Shapiro, S. D. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277, 2002-2004 (1997).
117. Hunninghake, G. M. et al. MMP12, lung function, and COPD in high-risk populations. N. Engl. J. Med. 361, 2599-2608 (2009).
118. Acuff, H. B. et al. Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res. 66, 7968-7975 (2006).
119. Houghton, A. M. et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 66, 6149-6155 (2006).
120. Cornelius, L. A. et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161, 6845-6852 (1998).
121. Kuhn, C., Yu, S. Y., Chraplyvy, M., Linder, H. E. & Senior, R. M. The induction of emphysema with elastase. II. Changes in connective tissue. Lab Invest. 34, 372-380 (1976).
122. Shapiro, S. D. et al. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am. J. Pathol. 163, 2329-2335 (2003).
123. Houghton, A. M. et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Med. 16, 219-223 (2010).
124. Foekens, J. A. et al. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. Cancer Res. 63, 337-341 (2003).
125. Akizuki, M. et al. Prognostic significance of immunoreactive neutrophil elastase in human breast cancer: long-term follow-up results in 313 patients. Neoplasia 9, 260-264 (2007).
126. Houghton, A. M. et al. Elastin fragments drive disease progression in a murine model of emphysema. J. Clin. Invest. 116, 753-759 (2006).
127. Mydel, P. et al. Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. J. Biol. Chem. 283, 9513-9522 (2008).
128. Weathington, N. M. et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nature Med. 12, 317-323 (2006).
129. Aberle, D. R. et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409 (2011).
130. Tammemagi, C. M. et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J. Natl Cancer Inst. 103, 1058-1068 (2011).
131. Parimon, T. et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175, 712-719 (2007).
132. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007).
133. Stolina, M. et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164, 361-370 (2000).
134. Khuri, F. R. et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7, 861-867 (2001).
135. Greenhough, A. et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30, 377-386 (2009).
136. Mao, J. T. et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev. Res. 4, 984-993 (2011).
137. Solomon, S. D. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080 (2005).
138. Heasley, L. E. et al. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J. Biol. Chem. 272, 14501-14504 (1997).
139. Keith, R. L. et al. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res. 64, 5897-5904 (2004).
140. Keith, R. L. et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev. Res. 4, 793-802 (2011).
141. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 93, 391-398 (1980).
142. Ito, K. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967-1976 (2005).
143. Adcock, I. M., Chung, K. F., Caramori, G. & Ito, K. Kinase inhibitors and airway inflammation. Eur. J. Pharmacol. 533, 118-132 (2006).
144. Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
145. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
146. Woodruff, P. G. et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181, 438-445 (2010).
147. Hammerman, P. S. et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
148. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
149. Witschi, H. et al. The carcinogenicity of environmental tobacco smoke. Carcinogenesis 18, 575-586 (1997).
150. Hubbard, R., Venn, A., Lewis, S. & Britton, J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 161, 5-8 (2000).
151. Sandford, A. J., Weir, T. D., Spinelli, J. J. & Pare, P. D. Z and S mutations of the α1-antitrypsin gene and the risk of chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol. 20, 287-291 (1999).
152. Yang, P. et al. α1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol. Biomarkers Prev. 8, 461-465 (1999).
153. Zhu, Y., Spitz, M. R., Lei, L., Mills, G. B. & Wu, X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res. 61, 7825-7829 (2001).
154. Cheng, S. L., Yu, C. J. & Yang, P. C. Genetic polymorphisms of cytochrome p450 and matrix metalloproteinase in chronic obstructive pulmonary disease. Biochem. Genet. 47, 591-601 (2009).
155. Dialyna, I. A., Miyakis, S., Georgatou, N. & Spandidos, D. A. Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol. Rep. 10, 1829-1835 (2003).
156. Xiao, D. et al. Relationship between polymorphisms of genes encoding microsomal epoxide hydrolase and glutathione S-transferase P1 and chronic obstructive pulmonary disease. Chin. Med. J. 117, 661-667 (2004).
157. Park, J. Y., Chen, L., Wadhwa, N. & Tockman, M. S. Polymorphisms for microsomal epoxide hydrolase and genetic susceptibility to COPD. Int. J. Mol. Med. 15, 443-448 (2005).
158. Benhamou, S., Reinikainen, M., Bouchardy, C., Dayer, P. & Hirvonen, A. Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res. 58, 5291-5293 (1998).
159. Kao, R. C., Wehner, N. G., Skubitz, K. M., Gray, B. H. & Hoidal, J. R. Proteinase 3. A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J. Clin. Invest. 82, 1963-1973 (1988).
160. Zheng, T. et al. Role of cathepsin S-dependent epithelial cell apoptosis in IFN-γ-induced alveolar remodeling and pulmonary emphysema. J. Immunol. 174, 8106-8115 (2005).
161. Yang, Y. et al. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J. Proteome Res. 9, 4767-4778 (2010).
162. Yang, Z. & Cox, J. L. Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int. 7, 8 (2007).
163. Golovatch, P. et al. Role for cathepsin K in emphysema in smoke-exposed guinea pigs. Exp. Lung Res. 35, 631-645 (2009).
164. Brooks, P. C. et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin α v β 3. Cell 85, 683-693 (1996).
165. Radisky, D. C. et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436, 123-127 (2005).
166. Balbin, M. et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nature Genet. 35, 252-257 (2003).
167. Kudo, Y. et al. Matrix Metalloproteinase-13 (MMP-13) Directly and indirectly promotes tumor angiogenesis. J. Biol. Chem. 287, 38716-38728 (2012).
168. Deshmukh, H. S. et al. Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production. Am. J. Respir. Crit. Care Med. 180, 834-845 (2009).
169. Hotary, K., Li, X. Y., Allen, E., Stevens, S. L. & Weiss, S. J. A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev. 20, 2673-2686 (2006).